TRIUMPH-T2D: Retatrutide in Adults with Type 2 Diabetes
NCT05929547 · Eli Lilly
- Phase
- Phase 3
- Enrollment
- 1,800 participants
- Est. completion
- Q4 2026
- Sponsor
- Eli Lilly
Background
TRIUMPH-T2D is a Phase 3, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of retatrutide (LY3437943) in adults with type 2 diabetes. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist. The trial tests three dose levels (4 mg, 8 mg, 12 mg) versus placebo over 52 weeks.
Primary endpoint
Change in HbA1c from baseline at 52 weeks
Secondary endpoints
- Change in body weight from baseline at 52 weeks
- Proportion of participants achieving HbA1c < 7.0%
- Change in fasting plasma glucose
- Change in systolic blood pressure
Population
Adults with type 2 diabetes (HbA1c 7–10%), BMI ≥ 27 kg/m²
Intervention
Retatrutide 4 mg, 8 mg, or 12 mg SC once weekly vs. placebo; dose escalation over 24 weeks
Inclusion criteria
Adults ≥ 18 years; type 2 diabetes diagnosis ≥ 6 months; HbA1c 7.0–10.0%; BMI ≥ 27 kg/m²; stable weight (< 5% change in prior 3 months)
Exclusion criteria
Type 1 diabetes; eGFR < 30 mL/min/1.73m²; personal or family history of medullary thyroid carcinoma or MEN2; recent cardiovascular event (< 3 months); use of GLP-1 RA or GIP agonist in prior 3 months
Trial information sourced from ClinicalTrials.gov and published literature. TryTrutide is not affiliated with Eli Lilly or any trial site. This is not medical advice.